Article
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
The Lancet. Oncology - 1 Oct 2015
Le Tourneau Christophe, Delord Jean-Pierre, Gonçalves Anthony, Gavoille Céline, Dubot Coraline, Isambert Nicolas, Campone Mario, Trédan Olivier, Massiani Marie-Ange, Mauborgne Cécile, Armanet Sebastien, Servant Nicolas, Bièche Ivan, Bernard Virginie, Gentien David, Jezequel Pascal, Attignon Valéry, Boyault Sandrine, Vincent-Salomon Anne, Servois Vincent, Sablin Marie-Paule, Kamal Maud, Paoletti Xavier
Abstract excerpt
BACKGROUND: Molecularly targeted agents have been reported to have anti-tumour activity for patients whose tumours harbour the matching molecular alteration. These results have led to increased off-label use of molecularly targeted agents on the basis of identified molecular alterations. We assessed the efficacy of several molecularly targeted agents marketed in France, which were chosen on the basis of tumour...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.